✦ LIBER ✦

Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis

✍ Scribed by V Cocquyt; S Van Belle; R.R Reinhardt; M.L.A Decramer; M O'Brien; J.H.M Schellens; M Borms; L Verbeke; F Van Aelst; M De Smet; A.D Carides; K Eldridge; B.J Gertz

Book ID: 117657124
Publisher: Elsevier Science
Year: 2001
Tongue: English
Weight: 177 KB
Volume: 37
Category: Article
ISSN: 0959-8049
DOI: 10.1016/s0959-8049(00)00416-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Prevention of cisplatin-induced acute an

Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869 : A randomized controlled trial

✍ Simon Van Belle; Michael R. Lichinitser; Rudolph M. Navari; August M. Garin; Mar 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 109 KB 👁 1 views

## Abstract ## BACKGROUND Recent studies have suggested that antiemetic therapy with a triple combination of the neurokinin‐1 receptor antagonist MK‐869, a serotonin (5‐HT~3~) antagonist, and dexamethasone provides enhanced control of cisplatin‐induced emesis compared with standard therapy regimen

Randomised comparison of ondansetron plu

Randomised comparison of ondansetron plus dexamethasone with dexamethasone alone for the control of delayed cisplatin-induced emesis

✍ H. Tsukada; T. Hirose; A. Yokoyama; Y. Kurita 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 153 KB

Fosaprepitant dimeglumine (MK-0517 or L-

Fosaprepitant dimeglumine (MK-0517 or L-785,298), an intravenous neurokinin-1 antagonist for the prevention of chemotherapy induced nausea and vomiting

✍ Van Belle, Simon JP; Cocquyt, Veronique 📂 Article 📅 2008 🏛 Informa plc 🌐 English ⚖ 311 KB

An open-label dose comparison study of o

An open-label dose comparison study of ondansetron for the prevention of emesis associated with chemotherapy prior to bone marrow transplantation

✍ Cynthia L. Osowski; Suzanne P. Dix; Mike Lynn; Terri Davidson; Lisa Cohen; Tammi 📂 Article 📅 1998 🏛 Springer-Verlag 🌐 English ⚖ 105 KB

Batanopride (BMY-25801): A new 5-HT3 rec

Batanopride (BMY-25801): A new 5-HT3 receptor antagonist for the prevention of cancer chemotherapy-induced emesis

✍ Smaldone, L.; Plezia, P.; Alberts, D.; Aapro, M.; Sartiano, G.; Dorn, M.; Brady, 📂 Article 📅 1990 🏛 Elsevier Science 🌐 English ⚖ 608 KB

Phase 2 trial results with the novel neu

Phase 2 trial results with the novel neurokinin-1 receptor antagonist casopitant in combination with ondansetron and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in cancer patients receiving moderately emetogenic chemotherapy

✍ Wichit Arpornwirat; Istvan Albert; Vincent L. Hansen; Jeremey Levin; Rajesh R. B 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 172 KB 👁 1 views